DOT1L and breast carcinoma: To assess whether DOT1L inhibition activates immune responses against breast cancer cells, we co-cultured PBMCs, including lymphocytes, with breast cancer cells pre-treated with a DOT1L inhibitor (Supplementary Fig. S7A, S7B).